First-in-human phase 0 study of (111)In-CHX-A”-DTPA trastuzumab for HER2 tumor imaging

INTRODUCTION: Tumors over-expressing the human epithelial receptor 2 (HER2) or exhibiting amplification or mutation of its proto-oncogene have a poorer prognosis. Using trastuzumab and/or other HER2 targeted therapies can increase overall survival in patients with HER2(+) tumors making it critical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurdziel, KA, Mena, E, McKinney, Y, Wong, K, Adler, S, Sissung, T, Lee, J, Lipkowitz, S, Lindenberg, L, Turkbey, B, Kummar, S, Milenic, DE, Doroshow, JH, Figg, WD, Merino, MJ, Paik, CH, Brechbiel, MW, Choyke, PL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425962/
https://www.ncbi.nlm.nih.gov/pubmed/30906574
http://dx.doi.org/10.15761/JTS.1000269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425962/
https://www.ncbi.nlm.nih.gov/pubmed/30906574
http://dx.doi.org/10.15761/JTS.1000269

Ejemplares similares